CD274 and lung cancer: In a study by Reck et al. (2021) on patients with non–small cell lung cancer (NSCLC) and a PD-L1 (programmed cell death-ligand 1) tumor proportion score of ≥50%, the survival rate in the group treated with pembrolizumab (31.9%) was significantly higher than that in the group treated with chemotherapy (16.3%).